.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Bone marrow aspirate concentrate has been promoted as a regenerative option for knee osteoarthritis, but high-quality clinical evidence remains limited. In this prospective randomized placebo-controlled trial, patients with mild-to-moderate knee osteoarthritis received bone marrow aspirate concentrate in one knee and saline placebo in the other, allowing within-patient comparison. The study evaluated pain, function and structural outcomes over follow-up and demonstrated that BMAC is feasible and generally well tolerated, while also highlighting the uncertainty around its magnitude of benefit compared with placebo. The clinical relevance of the study is that it moved BMAC evaluation beyond uncontrolled case series and into a randomized framework. However, the relatively small sample size means that the results should not be treated as definitive proof of disease modification. For orthopaedic practice, BMAC remains an evolving intervention whose biological rationale is stronger than the current certainty of clinical evidence. Patient selection, expectation management and transparent discussion of alternatives are therefore essential. Conventional evidence-based OA care—including exercise, weight management where appropriate, symptom control and consideration of established injections or arthroplasty when indicated—should not be displaced by regenerative marketing.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Bone marrow aspirate concentrate has been promoted as a regenerative option for knee osteoarthritis, but high-quality clinical evidence remains limited. In this prospective randomized placebo-controlled trial, patients with mild-to-moderate knee osteoarthritis received bone marrow aspirate concentrate in one knee and saline placebo in the other, allowing within-patient comparison. The study evaluated pain, function and structural outcomes over follow-up and demonstrated that BMAC is feasible and generally well tolerated, while also highlighting the uncertainty around its magnitude of benefit compared with placebo. The clinical relevance of the study is that it moved BMAC evaluation beyond uncontrolled case series and into a randomized framework. However, the relatively small sample size means that the results should not be treated as definitive proof of disease modification. For orthopaedic practice, BMAC remains an evolving intervention whose biological rationale is stronger than the current certainty of clinical evidence. Patient selection, expectation management and transparent discussion of alternatives are therefore essential. Conventional evidence-based OA care—including exercise, weight management where appropriate, symptom control and consideration of established injections or arthroplasty when indicated—should not be displaced by regenerative marketing.
last month
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
6 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
Last week
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Last week
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Last week
